A new early-stage clinical trial found that a novel monoclonal antibody provided dose-dependent full protection against the ...

Gyre Pharmaceuticals has completed participant enrolment for its 52-week Phase III clinical trial assessing Pirfenidone ...

Partnership further supports trial recruitment; FORTITUDE-HCM to be highlighted at upcoming HCMA Annual Patient MeetingEnrollment underway for ...

EV25 was generally well-tolerated and demonstrated a good safety profile, with no observable dose-dependent safety trends.

Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio of investigational therapies and ...

Gyre Therapeutics (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today ...

The study was led by Dr. Jia Sun from the Department of Endocrinology, Zhujiang Hospital of Southern Medical University, ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca ...

Telitacicept, a new dual inhibitor of the cytokines B-lymphocyte stimulator (BLyS) and APRIL (a proliferation-inducing ligand ...

Baxdrostat, a novel aldosterone synthase inhibitor, demonstrated a highly clinically meaningful reduction in 24-hour ...

Detailed price information for Tvardi Therapeutics Inc (TVRD-Q) from The Globe and Mail including charting and trades.

Merck reports phase 3 KEYNOTE-B96 trial meets secondary endpoint of OS in all comers population of patients with platinum-resistant recurrent ovarian cancer: Rahway, New Jersey Sa ...